Didanosine is an HIV medicine that belongs to the group of antiretroviral drugs. Usually Didanosine is used in combination with other medicines to treat HIV. However, Didanosine may reduce the viral load in the blood without completely preventing the risk of spreading HIV to others.

As all professional societies recommend in their guidelines, patients with chronic HBV should receive antiviral prophylaxis when they start non-TNF-targeted biologics. In patients with resolved HBV, the rates of HBV reactivation without antiviral prophylaxis in patients receiving IL-23, IL-17, and JAK inhibitors were up to 2.3%, 4.2%, and 0%, respectively.